188 related articles for article (PubMed ID: 20153368)
1. Dietary flavonoids in cancer therapy and prevention: substrates and inhibitors of cytochrome P450 CYP1 enzymes.
Androutsopoulos VP; Papakyriakou A; Vourloumis D; Tsatsakis AM; Spandidos DA
Pharmacol Ther; 2010 Apr; 126(1):9-20. PubMed ID: 20153368
[TBL] [Abstract][Full Text] [Related]
2. CYP1-mediated antiproliferative activity of dietary flavonoids in MDA-MB-468 breast cancer cells.
Androutsopoulos VP; Ruparelia K; Arroo RR; Tsatsakis AM; Spandidos DA
Toxicology; 2009 Oct; 264(3):162-70. PubMed ID: 19666078
[TBL] [Abstract][Full Text] [Related]
3. Comparative CYP1A1 and CYP1B1 substrate and inhibitor profile of dietary flavonoids.
Androutsopoulos VP; Papakyriakou A; Vourloumis D; Spandidos DA
Bioorg Med Chem; 2011 May; 19(9):2842-9. PubMed ID: 21482471
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors and prodrugs targeting CYP1: a novel approach in cancer prevention and therapy.
Cui J; Li S
Curr Med Chem; 2014; 21(5):519-52. PubMed ID: 24083611
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferative and cytostatic effects of the natural product eupatorin on MDA-MB-468 human breast cancer cells due to CYP1-mediated metabolism.
Androutsopoulos V; Arroo RR; Hall JF; Surichan S; Potter GA
Breast Cancer Res; 2008; 10(3):R39. PubMed ID: 18454852
[TBL] [Abstract][Full Text] [Related]
6. Discovery of cytochrome P450 1B1 inhibitors as new promising anti-cancer agents.
Chun YJ; Kim S
Med Res Rev; 2003 Nov; 23(6):657-68. PubMed ID: 12939788
[TBL] [Abstract][Full Text] [Related]
7. Flavonoids as RTK inhibitors and potential anticancer agents.
Teillet F; Boumendjel A; Boutonnat J; Ronot X
Med Res Rev; 2008 Sep; 28(5):715-45. PubMed ID: 18080331
[TBL] [Abstract][Full Text] [Related]
8. Chemopreventive and therapeutic modulation of green tea polyphenols on drug metabolizing enzymes in 4-Nitroquinoline 1-oxide induced oral cancer.
Srinivasan P; Suchalatha S; Babu PV; Devi RS; Narayan S; Sabitha KE; Shyamala Devi CS
Chem Biol Interact; 2008 Apr; 172(3):224-34. PubMed ID: 18336807
[TBL] [Abstract][Full Text] [Related]
9. Modeling and synthesis of novel tight-binding inhibitors of cytochrome P450 2C9.
Peng CC; Rushmore T; Crouch GJ; Jones JP
Bioorg Med Chem; 2008 Apr; 16(7):4064-74. PubMed ID: 18255300
[TBL] [Abstract][Full Text] [Related]
10. Potential toxicity of flavonoids and other dietary phenolics: significance for their chemopreventive and anticancer properties.
Galati G; O'Brien PJ
Free Radic Biol Med; 2004 Aug; 37(3):287-303. PubMed ID: 15223063
[TBL] [Abstract][Full Text] [Related]
11. Compound lipophilicity for substrate binding to human P450s in drug metabolism.
Lewis DF; Jacobs MN; Dickins M
Drug Discov Today; 2004 Jun; 9(12):530-7. PubMed ID: 15183161
[TBL] [Abstract][Full Text] [Related]
12. Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase).
Jones BC; Hawksworth G; Horne VA; Newlands A; Morsman J; Tute MS; Smith DA
Drug Metab Dispos; 1996 Feb; 24(2):260-6. PubMed ID: 8742240
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of CYP2C9 inhibition by flavones and flavonols.
Si D; Wang Y; Zhou YH; Guo Y; Wang J; Zhou H; Li ZS; Fawcett JP
Drug Metab Dispos; 2009 Mar; 37(3):629-34. PubMed ID: 19074529
[TBL] [Abstract][Full Text] [Related]
14. Bioactivation of the citrus flavonoid nobiletin by CYP1 enzymes in MCF7 breast adenocarcinoma cells.
Surichan S; Androutsopoulos VP; Sifakis S; Koutala E; Tsatsakis A; Arroo RR; Boarder MR
Food Chem Toxicol; 2012 Sep; 50(9):3320-8. PubMed ID: 22743247
[TBL] [Abstract][Full Text] [Related]
15. Update on uses and properties of citrus flavonoids: new findings in anticancer, cardiovascular, and anti-inflammatory activity.
Benavente-García O; Castillo J
J Agric Food Chem; 2008 Aug; 56(15):6185-205. PubMed ID: 18593176
[TBL] [Abstract][Full Text] [Related]
16. Flavonoids and Naphthoflavonoids: Wider Roles in the Modulation of Cytochrome P450 Family 1 Enzymes.
Dong J; Zhang Q; Cui Q; Huang G; Pan X; Li S
ChemMedChem; 2016 Oct; 11(19):2102-2118. PubMed ID: 27551833
[TBL] [Abstract][Full Text] [Related]
17. Effects of 8-methoxypsoralen on cytochrome P450 2A13.
von Weymarn LB; Zhang QY; Ding X; Hollenberg PF
Carcinogenesis; 2005 Mar; 26(3):621-9. PubMed ID: 15579482
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of rat hepatic aryl hydrocarbon hydroxylase activity by a series of 7-hydroxy coumarins: QSAR studies.
Lewis DF; Lake BG; Ioannides C; Parke DV
Xenobiotica; 1994 Sep; 24(9):829-38. PubMed ID: 7810165
[TBL] [Abstract][Full Text] [Related]
19. Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants.
Melet A; Marques-Soares C; Schoch GA; Macherey AC; Jaouen M; Dansette PM; Sari MA; Johnson EF; Mansuy D
Biochemistry; 2004 Dec; 43(49):15379-92. PubMed ID: 15581350
[TBL] [Abstract][Full Text] [Related]
20. Cancer phytotherapeutics: role for flavonoids at the cellular level.
Kale A; Gawande S; Kotwal S
Phytother Res; 2008 May; 22(5):567-77. PubMed ID: 18398903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
